Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

about

The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).

P2860

Q47305467-143558E8-3676-4C2F-9D51-6C36BE464658

P2860

Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

Item

http://www.wikidata.org/entity/Q40706247

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment durability and virol ...... n: an Australian cohort study.

@en

type

Item

label

Treatment durability and virol ...... n: an Australian cohort study.

@en

prefLabel

Treatment durability and virol ...... n: an Australian cohort study.

@en

P1476

Treatment durability and virol ...... en: an Australian cohort study

@en

P2093

Darren Russell

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Don Smith

http://www.w3.org/2001/XMLSchema#string

Maree O Sullivan

http://www.w3.org/2001/XMLSchema#string

Stephen Wright

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Raltegravir with optimized background therapy for resistant HIV-1 infection

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

P31

scholarly article

P356

10.1071/SH15210

http://www.w3.org/2001/XMLSchema#string

P50

Ian J. Woolley

Nicole De La Mata

Matthew Law

P577

2016-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27097796

http://www.w3.org/2001/XMLSchema#string

P921

virology

P932

5074908

http://www.w3.org/2001/XMLSchema#string

Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

about

P2860

P2860

Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921

P932